MSD sets sights on bispecific antibody market with Curon acqusition
For an upfront payment of $700m, MSD will gain access to the CD3 and CD19-targeting bispecific antibody CN201.
For an upfront payment of $700m, MSD will gain access to the CD3 and CD19-targeting bispecific antibody CN201.
What's Your Reaction?
